Skip to content

Ginkgo Bioworks DNA Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

Azenta logo
AzentaAZTA
0
ClearPoint Neuro logo
ClearPoint NeuroCLPT
0
Charles River Laboratories logo
Charles River LaboratoriesCRL
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's convertible preferred stock issued shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's convertible preferred stock issued shares?
Ginkgo Bioworks (DNA) reported convertible preferred stock issued shares of 0 in Q1 2026.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.